Myxofibrosarcoma
Therapeutic area
Oncology
Rare disease
Yes
- Definition
- A malignant fibroblastic neoplasm arising from the soft tissue. It is characterized by the presence of spindle-shaped cells, cellular pleomorphism, thin-walled blood vessels, fibrous septa, and myxoid stroma.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Myxofibrosarcoma
- Therapeutic area
- Oncology
- myxofibrosarcoma
- fibromyxosarcoma
- myxofibrosarcoma
- myxoid MFH
- myxoid fibrous histiocytoma
- myxoid malignant fibrous histiocytoma
- MFS
- All therapeutic areas
- Oncology
- Severity
- Severe
- MONDO ID
- MONDO:0019202
- Parent condition
- MONDO:0018078
Related records
Broader conditions (12)
- Cancer
- Cancer or benign tumor
- Connective and soft tissue neoplasm
- Disease
- Disease by etiologic mechanism
- Human disease
- Malignant soft tissue neoplasm
- Neoplasm
- Neoplastic disease or syndrome
- Sarcoma
- Soft tissue neoplasm
- Soft tissue sarcoma
Trials (20)
- A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
- A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
- A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg
- Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
- Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma
- CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma
- Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma.
- Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
- ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma
- Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma
- Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall
- Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma
- Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma
- NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
- Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
- Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
- Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery
- Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
- Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas
- Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma